Abstract
In the last few years the number of calcium antagonists available for treatment has increased rapidly since these drugs were shown to be effective in the treatment of stable and unstable angina pectoris. Gallopamil is a new calcium antagonist which appears to be three to four times more potent in animals than verapamil (3,4). About 90% of the dose of gallopamil is absorbed and its bioavailability is about 25% (21). Studies in patients give a mean half-life of 2.8 to 4.8 hours (21), with the concentrations of the unchanged substance peaking one to 2 hours after administration (20). After intravenous administration, this drug dilates the arteries and veins (5, 14), reduces peripheral arterial resistance and the work of the heart (−13%), and myocardial oxygen uptake (−10%), (12). It also dilates the epicardial coronary vessels and prevents vasospasm (10, 11): Gallopamil reduces sino-atrial node excitability and slows conduction in the AV node (4, 6).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alderman EL, Davies RO, Crowley JJ et al. (1975) Dose response effectiveness of Propranolol for the treatment of angina pectoris, Circulation 51:964–975
Anderson JL, Wagner JM, Datz FL, Christian PE, Bray BE, Taylor AT (1984) Comparative effects of Diltiazem, Propranolol and Placebo on exercise performance using radionuclide ventriculography in patients with symptomatic coronary artery disease: results of a double-blind, randomized, crossover study. Am Heart J 107:698–706.
Fleckenstein A, Tritthart H, Fleckenstein B, Herbst A, Grün G (1969) Eine neue Gruppe kompetitiver Ca++-Antagonisten (Iproveratril, D 600, Prenylamin) mit starken Hemmeffekten auf die elektromechanische Koppelung im Warmblutmyokard. Pflügers Arch Ges Physiol 307:R25
Fleckenstein A, Fleckenstein B, Späth F, Byon YK (1984) Gallopamil (D 600) — a calcium antagonist of high potency and specifiCity. Effects on the myocardium and pacemakers. In: Kaltenbach M, Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 1–32
Fleckenstein-Grün G, Fleckenstein A (1984) Blockade of the Ca++-dependent bioelectrical automatiCity and electromechanical coupling of smooth muscle cells by gallopamil (D 600). In: Kaltenbach M, Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 33–48
Fleckenstein A (1980) Steuerung der myokardialen Kontraktilität, ATP-Spaltung, Atmungsinten-sität und Schrittmacherfunktion durch Calcium-Ionen-Wirkungsmechanismus der Calcium-Antagonisten. In: Fleckenstein A, Roskamm H (eds) Calcium-Antagonisten. Springer, Berlin Heidelberg New York, pp. 1–28
Frishman WH, Klein NA, Strom JA, Willens H, Lejemtel TH, Jentzer J, Siegel L, Klein P, Kirschen N, Silverman R, Pollack S, Doyle R, Kirsten E, Sonnenblick EH (1982) Superiority of Verapamil to Propranolol in stable angina pectoris: a double-blind, randomized crossover trial. Circulation 65 (Suppl):51–59
Hopf R, Drews H, and Kaltenbach M (1984) Anti-anginal effect of gallopamil as compared with nifedipine. In: Kaltenbach M, Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 123–131
Khurmi NS, O’Hara MJ, Bowles MJ, Bala Subramanian V, and Raftery EB (1984) Randomized double-blind comparison of Gallopamil and Propranolol in stable angina pectoris. Am J Cardiol 53:684–688
Kohlhardt M, Bauer B, Krause H, Fleckenstein A (1972) Differentiation of the transmembrane Na+ and Ca++ channel in mammalian cardiac fibres by the use of specific inhibitors. Pflügers Arch Ges Physiol 335:309
Kovách AGB, Ligeti L, Bakos M, Rubanyi G, Koller A (1984) Studies in vitro and in vivo on the effects of gallopamil on coronary vessels. In: Kaltenbach M, Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 58–65
Lehmann HU, Taegener-Torge C, Witt E, Beck OA, Hochrein M (1979) Antiarrhythmischer Wirkungsvergleich zwischen Gallopamil (D 600) und Verapamil. Angiocard 2:103–111
Mitrović K, Nimelä L, Neuss N, and Schlepper M (1984): Antianginal effect of the calcium antagonist gallopamil. In: Kaltenbach M, Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 107–113
Raschack M, Gries J, Bühler V, Maurer R (1984) Studies of the cardiovascular effects of gallopamil. In: Kaltenbach M, Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 72–80
Robertson RM, Wood AJJ, Vaughan WK, and Robertson D (1982) Exacerbation of vasotonic angina pectoris by Propranolol. Circulation 65:281–285
Sadick NN, Tan ATH, Fletcher PJ, Morris J, Kelly DT (1982) A double-blind randomized trial of Propranolol and Verapamil in the treatment of effort angina. Circulation 66:574–579
Sesto M, Ivancić R, Custović F (1984) The effect of gallopamil on the haemodynamics of patients with coronary heart disease. In: Kaltenbach M, Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 94–99
Smoker PE, MacAlpin RN, Alvaro A, Kattus AA (1972) Reproducibility of a multi-stage near maximal treadmill test for exercise tolerance in angina pectoris. Circulation 48:346
Starling MR, Moody M, Crawford MH, Levi B, O’Rourke RA (1984) Repeat treadmill exercise testing: variability of results in patients with angina pectoris. Am Heart J 107:298–303
Stieren B, Bühler V, Hege HG, Hollmann M, Neuss H, Schlepper M, and Weymann J (1984) Pharmacokinetics and metabolism of gallopamil. In: Kaltenbach M and Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 88–93
Sučić MJ, Bühler V, Kehrhahn OH and Stieren B (1980) Zur Pharmakokinetik und Pharmakody-namik von Gallopamil. Report VP/FMK/FMH 8005 dated 28. 10. 80. Medical Research and Development Department, Pharmaceuticals Division, BASF Aktiengesellschaft
Sučić MJ, Schiemann J (1984) Results of an open multicentre study with 455 patients with coronary heart disease, treated with gallopamil for 1 year. In: Kaltenbach M, Hopf R (eds) Gallopamil, Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 132–135
Theisen F, Jahrmärker H (1984) Effect of gallopamil (D 600) on the ECG during exercise in coronary heart disease. In: Kaltenbach M, Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 117–122
Zar J (1974) Biostatistical Analysis. Englewood Cliffs, New York, Prentice Hall
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt
About this paper
Cite this paper
Scrutinio, D. et al. (1989). Treatment of chronic stable angina pectoris with gallopamil. In: Bender, F., Meesmann, W. (eds) Treatment with Gallopamil. Steinkopff. https://doi.org/10.1007/978-3-642-85376-0_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-85376-0_11
Publisher Name: Steinkopff
Print ISBN: 978-3-642-85378-4
Online ISBN: 978-3-642-85376-0
eBook Packages: Springer Book Archive